1993
Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: A pilot study
Chappell P, Leckman J, Scahill L, Hardin M, Anderson G, Cohen D. Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: A pilot study. Psychiatry Research 1993, 47: 267-280. PMID: 8396784, DOI: 10.1016/0165-1781(93)90084-t.Peer-Reviewed Original ResearchConceptsNormal control subjectsTourette syndromeTic frequencyControl subjectsTS patientsMicrograms/Clinician ratingsKappa agonist spiradolineInvolvement of opioidRole of opioidsGrowth hormone secretionDual modulatory effectsDose-response studyMotor tic frequencyMore growth hormoneTic symptomsHormone secretionNeuroendocrine effectsKappa receptorsPhonic ticsSpiradoline mesylateIntermediate doseLow doseModulatory effectsSpiradoline
1990
Growth hormone and prolactin response to methylphenidate in children with attention deficit disorder
Shaywitz B, Shaywitz S, Sebrechts M, Anderson G, Cohen D, Jatlow P, Young J. Growth hormone and prolactin response to methylphenidate in children with attention deficit disorder. Life Sciences 1990, 46: 625-633. PMID: 2308471, DOI: 10.1016/0024-3205(90)90131-a.Peer-Reviewed Original Research
1983
Acute and Chronic CLonidine Treatment in Tourette's Syndrome A Preliminary Report on Clinical Response and Effect on Plasma and Urinary Catecholamine Metabolites, Growth Hormone, and Blood Pressure
LECKMAN J, DETLOR J, HARCHERIK D, YOUNG J, ANDERSON G, SHAYWITZ B, COHEN D. Acute and Chronic CLonidine Treatment in Tourette's Syndrome A Preliminary Report on Clinical Response and Effect on Plasma and Urinary Catecholamine Metabolites, Growth Hormone, and Blood Pressure. Journal Of The American Academy Of Child & Adolescent Psychiatry 1983, 22: 433-440. PMID: 6579101, DOI: 10.1016/s0002-7138(09)61504-1.Peer-Reviewed Original ResearchConceptsChronic clonidine treatmentClonidine treatmentTourette syndromeHomovanillic acidHuman growth hormoneClinical responseBlood pressureGrowth hormoneΑ2-adrenergic receptor agonistTreatment of TSUrinary catecholamine metabolitesClinical response dataChronic neuropsychiatric disorderPlacebo-controlled conditionsA Preliminary ReportClonidine therapyOral clonidineNoradrenergic receptorsSingle doseUnknown etiologyFunctional statusReceptor agonistClinical trialsDopaminergic systemTS patients
1982
Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate.
Shaywitz S, Hunt R, Jatlow P, Cohen D, Young J, Pierce R, Anderson G, Shaywitz B. Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate. Pediatrics 1982, 69: 688-94. PMID: 7079034, DOI: 10.1542/peds.69.6.688.Peer-Reviewed Original ResearchConceptsAcute studyMPH concentrationsGrowth hormoneObserved maximal concentrationCentral dopaminergic mechanismsPeak plasma concentrationAdministration of medicationsPharmacokinetics of methylphenidatePlasma growth hormoneConcentrations of methylphenidatePlasma MPH concentrationsAttention deficit disorderClinical responseChronic treatmentDopaminergic mechanismsGroup of childrenDisorders of attentionAbbreviated Conners' Rating ScaleSchool-aged childrenOral administrationPlasma concentrationsClinical pharmacologyMPH administrationProlactin concentrationsPercentage of improvement
1981
Plasma free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette's Syndrome: Preliminary report
Young J, Cohen D, Hattox S, Kavanagh M, Anderson G, Shaywitz B, Maas J. Plasma free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette's Syndrome: Preliminary report. Life Sciences 1981, 29: 1467-1475. PMID: 6946271, DOI: 10.1016/0024-3205(81)90012-6.Peer-Reviewed Original ResearchConceptsFree MHPGPlasma free MHPGTourette syndromeChallenge doseNeuroendocrine responsesDoses of clonidineSingle oral dosesClonidine administrationResponsive patientsGH responseOral dosesMaintenance treatmentThyroxine indexClonidineTS patientsPatientsMHPGSyndromeT patientsNeuropsychiatric patientsPilot studyPreliminary reportMetabolic responseFurther investigationDose